Geode Capital Management LLC Grows Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Geode Capital Management LLC lifted its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) by 3.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,008,214 shares of the company’s stock after buying an additional 35,196 shares during the period. Geode Capital Management LLC’s holdings in CRISPR Therapeutics were worth $47,383,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Capital Advisors Inc. OK lifted its holdings in shares of CRISPR Therapeutics by 8.1% in the 3rd quarter. Capital Advisors Inc. OK now owns 300,589 shares of the company’s stock worth $14,122,000 after acquiring an additional 22,583 shares during the last quarter. Granite Bay Wealth Management LLC bought a new stake in CRISPR Therapeutics during the 2nd quarter valued at $2,375,000. State Street Corp raised its holdings in shares of CRISPR Therapeutics by 25.0% in the third quarter. State Street Corp now owns 2,992,988 shares of the company’s stock valued at $140,611,000 after acquiring an additional 599,304 shares in the last quarter. International Assets Investment Management LLC purchased a new stake in shares of CRISPR Therapeutics in the 3rd quarter worth approximately $1,825,000. Finally, FMR LLC lifted its holdings in CRISPR Therapeutics by 1.0% during the third quarter. FMR LLC now owns 2,376,166 shares of the company’s stock worth $111,632,000 after buying an additional 23,075 shares during the period. 69.20% of the stock is owned by institutional investors.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $55.10, for a total value of $826,500.00. Following the completion of the sale, the chief executive officer now directly owns 181,540 shares of the company’s stock, valued at approximately $10,002,854. The trade was a 7.63 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel James R. Kasinger sold 1,089 shares of the company’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the transaction, the general counsel now directly owns 62,597 shares of the company’s stock, valued at approximately $2,896,989.16. This represents a 1.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 50,382 shares of company stock valued at $2,744,179 over the last three months. 4.10% of the stock is currently owned by insiders.

CRISPR Therapeutics Price Performance

Shares of NASDAQ CRSP opened at $40.48 on Tuesday. The company has a market cap of $3.46 billion, a PE ratio of -14.30 and a beta of 1.62. The stock has a fifty day moving average price of $48.30 and a 200 day moving average price of $50.52. CRISPR Therapeutics AG has a 1-year low of $39.41 and a 1-year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The company had revenue of $0.60 million for the quarter, compared to analyst estimates of $6.65 million. During the same period in the prior year, the business posted ($1.41) earnings per share. Analysts anticipate that CRISPR Therapeutics AG will post -5.13 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have weighed in on CRSP. Barclays lowered their target price on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 6th. Needham & Company LLC reiterated a “buy” rating and issued a $84.00 target price on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a research report on Wednesday, December 11th. JMP Securities reaffirmed a “market outperform” rating and set a $86.00 target price on shares of CRISPR Therapeutics in a report on Friday. Finally, Chardan Capital restated a “buy” rating and issued a $94.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, December 10th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, CRISPR Therapeutics currently has a consensus rating of “Hold” and an average price target of $77.93.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.